Drug Trial Radar · NCT06796062
Psilocybin for Opioid Use Disorder (OUD)
Last checked: Nov 19, 2026Latest source record: Jan 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
480
Planned (sponsor's estimate)
Start
Dec 17, 2025
Primary completion
Feb 2029
Study completion Feb 2029
Sponsor
- Lead sponsor
- NYU Langone HealthAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute on Drug Abuse (NIDA)
- First posted
- Jan 28, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, care provider)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a double-blind, adaptive, 2-stage, multi-site, phase 2 randomized controlled clinical trial designed to evaluate effects of moderate and high dose psilocybin, relative to low-dose psilocybin control, in OUD patients who continue to use illicit opioids in spite of adherence to standard-of-care treatment with methadone. Up to 480 participations will be consented to yield 240 randomized participants. This study is part of the NIH HEAL Initiative (https://heal.nih.gov/). In Stage 1, subjects will be randomly assigned to one of three groups: psilocybin 30 mg (high dose), psilocybin 20 mg (medium dose), and psilocybin 1 mg (control condition). By the end of Stage 1, an interim statistical analysis will be performed. The study will proceed to Stage 2 if at least one of the active dosages of psilocybin demonstrates 1) acceptable safety, based on analysis of safety data from Stage 1; and 2) conditional power of at least 25%, based on effect size estimates for the primary opioid use outcome (weeks of biologically-verified abstinence during 24 weeks of follow-up). Using a priori decision rules, the interim analysis will determine which of the active treatment groups (30 mg, 20 mg, or both) will be retained in Stage 2 of the trial. Stage 2 will continue the study, using the same treatment and assessment protocols, but retaining only the active dosage or dosages with a high probability of demonstrating efficacy relative to the psilocybin 1 mg control condition. The primary aims are to 1) Evaluate safety and efficacy outcomes in Stage 1 subjects in order to optimize design of the Stage 2, 2) Determine whether treatment with a single high (30 mg) or medium (20 mg) dose of psilocybin improves OUD treatment outcomes, relative to psilocybin 1 mg (control condition), in patients who continue to use illicit opioids despite adherence to methadone treatment, 3) Evaluate the effects of high-dose psilocybin and medium dose psilocybin on self-reported OUD-related neuropsychopathology, and 4) Identify likely responders to psilocybin treatment by using machine learning to model post-treatment OUD outcomes, based on pretreatment characteristics including all relevant clinical data, evaluations, and questionnaires.
Conditions
- Opioid Use Disorder
Interventions
PsilocybinDrug
One capsule (1 mg, 20 mg, or 30 mg) administered once orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Stage 1: The number of weeks during the 24 week follow-up period with no illicit opioid useTime frame: Up to 24 weeks
- Stage 1: Number of adverse eventsTime frame: Up to 24 weeks
- Stage 1: Change in QTc during drug administration sessionTime frame: Up to 24 weeks
- Stage 2: The number of weeks during the 24 week follow-up period with no illicit opioid useTime frame: Up to 24 weeks
- Stage 2: Number of adverse eventsTime frame: Up to 24 weeks
- Stage 2: Change in QTc during drug administration sessionTime frame: Up to 24 weeks
- Stage 2: Total score on the Penn Craving Scale for OpioidsTime frame: Up to 24 weeks
- Stage 2: Score on the Negative Affect subscale of the Positive and Negative Affect ScaleTime frame: Up to 24 weeks
- Stage 2: Total score on the 20-item version of the Short Urgency, Premeditation, Perseverance, Sensation seeking, and Positive urgency (UPPS-P) Impulsive Behavior Scale (SUPPS-P)Time frame: Up to 24 weeks
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Duke City Recovery Toolbox
Albuquerque, New Mexico · Recruiting
University of New Mexico
Albuquerque, New Mexico · Recruiting
StartCare
Brooklyn, New York · Recruiting
NYU Langone Health
New York, New York · Recruiting
VIP Community Services, Inc
The Bronx, New York · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.